What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it nurtures dreams of one day growing into a fully integrated biopharma that can market its own products.

OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization of protein interactions than traditional drug discovery methods.

The UK prime minister will take advice from chief executives of companies ranging from ScottishPower, the energy supplier, and Lloyds Banking Group, to high street food store Greggs and pharma company OMass Therapeutics.

The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest rates) continued to negatively impact the capital markets and the fundraising environment. This has been demonstrated with the slowdown in the number of biotech companies attempting to IPO, but has also started to be felt in the private markets. There is continued downward pressure on valuations and all companies are trying to extend their runway to get to a larger value inflection point. Page 54

Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry techniques, next generation native mass spectrometry and custom chemistry to interrogate how a target interacts with its native ecosystem. Pages 76-81

Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well as canniness): “Financial markets remain tight so companies will need to dual track their strategic focus. With pharma deals likely more prevalent in 2024 having both platform and product assets that might be the basis of a strategic alliance will both help fuel pharma pipelines and fund biotechs through to a more favourable climate..."

OMass leverages novel biochemistry techniques, native mass spectrometry and custom chemistry to develop small molecule therapeutics against well-validated but intractable or inadequately drugged targets, focusing on immunological and rare diseases. Page 59

Always up for a new challenge, Ros describes the many twists and turns her career has taken over the years. Her story highlights that it is never too late for a person to change direction and seek an alternative avenue should they find their skills do not fit the job they have landed in.

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s work, including her recent publication in Nature, highlights...

UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases...

Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive $100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform, which is based on mass spectrometry, could open the door to an innovative approach to drug discovery...

OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five small-molecule programs against previously intractable membrane-bound targets to the clinic...

Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery...

OMass Therapeutics have announced the $100 million (£75.5 million) Series B financing to progress its drug pipeline in immunology and rare diseases. OMass is a biotechnology company that identifies medicines against highly validated target ecosystems...

GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic...

April 28 (Reuters) - Betting on a fresh formula for the arduous, expensive and failure-prone field of drug discovery, UK-based OMass Therapeutics on Thursday said it has raised $100 million...

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development...

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets...

Included for 2022 are investors, CEOs of small and mid-sized companies, rising employees in larger biopharma and medtech businesses, as well as people driving unique health initiatives...

Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics...

Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University's first female Professor of Chemistry, former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass Therapeutics...

There’s not yet proof of the pudding, but OMass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small...

New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell surfaces that are the foundation of intracellular signaling…

When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond Deegan knew exactly what to do. She turned to a network of colleagues she developed through her past participation in the Executive Women In Bio Boardroom Ready Program…

Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund the development of drugs that target G protein-coupled receptors (GPCRs)…

The UK-based start-up OMass Therapeutics said on 17 February that it completed a series A extension totaling £27.5m ($35.7m) from existing investors Syncona Ltd and Oxford Sciences Innovation, who contributed £16.6m and £10.4m, respectively…

The technology used to detect explosives at airports — mass spectrometry — is being piloted as an engine for drug discovery…

Omass Therapeutics, of Oxford, U.K., which is harnessing mass spectrometry and other biophysical technologies to drive drug discovery, said it completed an extended series A financing of £27.5 million (US$35.757 million) from existing investors Syncona Ltd. and Oxford Sciences Innovation, bringing the total series A round to £41.5 million…

Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors…

Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside Oxford Sciences Innovation (OSI)…

OMass Therapeutics, which was spun out of Oxford in 2016, has secured £14 million in a Series A round of funding led by Syncona, the life sciences investment arm of the Wellcome Trust that has also invested in another Oxford spinout called Nightstar Therapeutics. OMass uses mass spectrometry platforms to discover and develop therapeutics…

A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to exploit expertise in "native" mass spectrometry, a technology investors believe has potential in helping to build a portfolio of novel drugs…